Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSGV1-PSCA-8T28Z in Metastatic Castration Resistant Prostate Cancer
NCT06193486Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2024
- Primary completion
- Jan 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PSCA gamma-delta CAR T-cell therapy in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Oct 2024; status: recruiting.
02
Drugs
PSCA gamma-delta CAR T-cell therapy
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06193486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193486.